Search | Clinical Trials Finder

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Positron Emission Tomography, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bone Metastases
Interventions: blood sampling, the SF-36 questionnaire; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
Interventions: Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography, Fludeoxyglucose F-18, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography, Resection; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT); Biological · Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Ovarian Neoplasms
Interventions: Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision; Procedure
Lead sponsor: Angle plc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Ipilimumab, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more

Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 138
States / cities: Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1150
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • St Louis, Missouri

Conditions: Cannabis Use Disorder
Interventions: Guided Imagery Laboratory Session; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Electronic Health Record Review, Multigated Acquisition Scan, Mycophenolate Mofetil, Reduced-Intensity Transplant Conditioning Procedure, Ruxolitinib, Survey Administration, Tacrolimus; Procedure · Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions: Aldesleukin, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Nivolumab, Oxaliplatin, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions: Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Months to 25 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 491
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 371 more

Conditions: CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
Interventions: Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2023
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Postural Tachycardia Syndrome
Interventions: Autonomic Function Testing, Posture Study, Measurement of Total Blood Volume, Exercise Capacity Test; Other · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2026
U.S. locations: 223
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 157 more

Conditions: Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nilotinib Hydrochloride Monohydrate, Paclitaxel; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 124
States / cities: Birmingham, Alabama • Kingman, Arizona • Palo Alto, California + 101 more

Conditions: There is no Focus on Any Specific Condition
Interventions: Peripheral intravenous catheter placement, Blood draw, Peripheral intravenous catheter, To keep open (TKO) infusion of 0.9% normal saline; Procedure · Other · Device + 1 more
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 90 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Colorectal Cancer
Interventions: bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET); Biological · Drug · Genetic + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions: Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 130
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 838
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more

Conditions: Leukemia
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more

Search by objective public record fields.

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Investigating Stress-related Mechanisms in the Laboratory and Real World in Individuals With Cannabis Use Disorder

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Antegrade Versus Retrograde IV for Blood Draws

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia